Dr. Roy Drucker

Chief Medical Officer

Dr. Roy Drucker joined the European R&D arm of Sterling Drug Inc. as a medical advisor and was promoted to be responsible for clinical pharmacology, drug metabolism, and bioanalysis in Europe. In 1986 he moved to the Upjohn Company (USA), subsequently Pharmacia & Upjohn, Inc., where he held a range of international positions including Director of Marketing with responsibility for worldwide marketing of cardiovascular products, Executive Director of European Community Affairs and Business Systems, and Vice-President of Drug Development with global responsibilities in multiple therapeutic areas, for clinical drug development and medical support for marketed products. In 1996 he joined Technomark Consulting Service Ltd. in the UK as General Manager and lead services to the healthcare and bioscience industries, while being the Fund Manager of Technomark's first venture capital fund. A graduate of the Harvard School Advanced Management Program, Member of the Securities Institute, and an FSA Registered Securities Representative, Roy obtained his MA and his medical qualifications from the University of Cambridge. Roy has been based in Belgium, the United States, and most recently the UK, India, and China. He has conducted business in Japan, North America, Western Europe, India, China, and Hong Kong.

Currently, Roy holds several global appointments, including Chief Medical Officer of Technomark Life Sciences and Chief Medical Officer of a bio-informatics company in the UK. He also serves as board member for Technomark, as well as board member of several other life science companies.